{
    "2018-12-16": [
        [
            {
                "time": "",
                "original_text": "国盛医药2019年度策略报告：医药进入非药、医保外细分领域的个股时代——论行业巨变下的生存法则推演",
                "features": {
                    "keywords": [
                        "医药",
                        "非药",
                        "医保外",
                        "细分领域",
                        "个股时代",
                        "行业巨变",
                        "生存法则"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "医疗器械板块投资机会相对突出【周观点|长江医药1216】",
                "features": {
                    "keywords": [
                        "医疗器械",
                        "投资机会",
                        "长江医药"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗器械"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}